A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study - Concepedia

Concepedia

Publication | Open Access

A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study

DOI Full Paper Access

43

Citations

16

References

2021

Year

Angioletta Lasagna, Francesco Agustoni, Elena Percivalle, Sabrina Borgetto, A. Crastes de Paulet, Giuditta Comolli, Antonella Sarasini, Federica Bergami, Josè Camilla Sammartino, Alessandro Ferrari,

Abstract

Our data have demonstrated that the administration of a full course of BNT162b2 vaccine elicited a sustained immune response against SARS-CoV-2 regardless of the type of cancer and/or the type of immune checkpoint inhibitors.

References

	Year	Citations

Page 1